The intact antibody of human immunoglobulin (IgG) is composed of the fragment for antigen
binding (Fab) and the crystallizable fragment (Fc) for binding of Fcγ receptors. Among the …

Monoclonal antibodies constitute a promising class of targeted anticancer agents that
enhance natural immune system functions to suppress cancer cell activity and eliminate …

Antibody-based therapies have garnered considerable success in recent years. This is due
to the availability of strategies to successfully engineer antibodies into humanized forms …

Bispecific antibodie (BsAbs) combine two or more epitope-recognizing sequences into a
single protein molecule. The first therapeutic applications of BsAbs were focused on cancer …

Targeted therapeutics such as monoclonal antibodies (mAbs) have proven successful as
cancer drugs. To profile products that could be marketed in the future, we examined the …

Bi-and multispecific antibody derivatives (bsAbs) can be considered as the next generation
of targeted biologics for cancer therapy. The general concept of bsAbs is a physical …

Recent advances in cancer immunotherapy using monoclonal antibodies have dramatically
revolutionized the therapeutic strategy against advanced malignancies, inspiring the …

The concept of using bispecific antibodies to retarget immune effector cells for cancer
therapy was conceived more than 20 years ago. However, initial clinical studies were rather …

With increasing numbers of bispecific antibodies (BsAbs) and multispecific products entering
the clinic, recent data highlight immunogenicity as an emerging challenge in the …

Monoclonal antibody-based targeted therapy has greatly improved treatment options for
patients. However, long-term efficacy of such antibodies is limited by resistance …